Protein kinase G as a therapeutic target for the treatment of metastatic colorectal cancer

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Colorectal cancer is a leading cause of cancer-related death in the world and there is an urgent need for new strategies to combat this disease. Findings from several independent laboratories have converged on cGMP signaling as an exciting new therapeutic target, but the mechanisms remain controversial. A key intracellular effector of cGMP is protein kinase G (PKG). This article reviews the scientific literature concerning PKG effects on tumor development and progression, and discusses possible strategies for its exploitation in future cancer therapies. Studies from several independent laboratories have described novel anti-tumor effects of PKG in colon cancer cells that include inhibition of tumor growth and angiogenesis. While more preclinical research is warranted to better understand signaling mechanisms, these properties support the notion that PKG is a novel cancer target.

Original languageEnglish (US)
Pages (from-to)367-376
Number of pages10
JournalExpert Opinion on Therapeutic Targets
Volume12
Issue number3
DOIs
StatePublished - Mar 1 2008

Fingerprint

Cyclic GMP-Dependent Protein Kinases
Colorectal Neoplasms
Tumors
Neoplasms
Therapeutics
Cells
Colonic Neoplasms
Growth
Research

Keywords

  • Angiogenesis
  • Apoptosis
  • Colon cancer
  • Metastasis
  • Nitric oxide
  • PKG
  • Phosphodiesterase
  • Uroguanylin
  • cGMP

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Protein kinase G as a therapeutic target for the treatment of metastatic colorectal cancer. / Browning, Darren D.

In: Expert Opinion on Therapeutic Targets, Vol. 12, No. 3, 01.03.2008, p. 367-376.

Research output: Contribution to journalReview article

@article{7bfeee6328ef4c0eaf0688e433d23e3c,
title = "Protein kinase G as a therapeutic target for the treatment of metastatic colorectal cancer",
abstract = "Colorectal cancer is a leading cause of cancer-related death in the world and there is an urgent need for new strategies to combat this disease. Findings from several independent laboratories have converged on cGMP signaling as an exciting new therapeutic target, but the mechanisms remain controversial. A key intracellular effector of cGMP is protein kinase G (PKG). This article reviews the scientific literature concerning PKG effects on tumor development and progression, and discusses possible strategies for its exploitation in future cancer therapies. Studies from several independent laboratories have described novel anti-tumor effects of PKG in colon cancer cells that include inhibition of tumor growth and angiogenesis. While more preclinical research is warranted to better understand signaling mechanisms, these properties support the notion that PKG is a novel cancer target.",
keywords = "Angiogenesis, Apoptosis, Colon cancer, Metastasis, Nitric oxide, PKG, Phosphodiesterase, Uroguanylin, cGMP",
author = "Browning, {Darren D}",
year = "2008",
month = "3",
day = "1",
doi = "10.1517/14728222.12.3.367",
language = "English (US)",
volume = "12",
pages = "367--376",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Protein kinase G as a therapeutic target for the treatment of metastatic colorectal cancer

AU - Browning, Darren D

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Colorectal cancer is a leading cause of cancer-related death in the world and there is an urgent need for new strategies to combat this disease. Findings from several independent laboratories have converged on cGMP signaling as an exciting new therapeutic target, but the mechanisms remain controversial. A key intracellular effector of cGMP is protein kinase G (PKG). This article reviews the scientific literature concerning PKG effects on tumor development and progression, and discusses possible strategies for its exploitation in future cancer therapies. Studies from several independent laboratories have described novel anti-tumor effects of PKG in colon cancer cells that include inhibition of tumor growth and angiogenesis. While more preclinical research is warranted to better understand signaling mechanisms, these properties support the notion that PKG is a novel cancer target.

AB - Colorectal cancer is a leading cause of cancer-related death in the world and there is an urgent need for new strategies to combat this disease. Findings from several independent laboratories have converged on cGMP signaling as an exciting new therapeutic target, but the mechanisms remain controversial. A key intracellular effector of cGMP is protein kinase G (PKG). This article reviews the scientific literature concerning PKG effects on tumor development and progression, and discusses possible strategies for its exploitation in future cancer therapies. Studies from several independent laboratories have described novel anti-tumor effects of PKG in colon cancer cells that include inhibition of tumor growth and angiogenesis. While more preclinical research is warranted to better understand signaling mechanisms, these properties support the notion that PKG is a novel cancer target.

KW - Angiogenesis

KW - Apoptosis

KW - Colon cancer

KW - Metastasis

KW - Nitric oxide

KW - PKG

KW - Phosphodiesterase

KW - Uroguanylin

KW - cGMP

UR - http://www.scopus.com/inward/record.url?scp=41049095471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41049095471&partnerID=8YFLogxK

U2 - 10.1517/14728222.12.3.367

DO - 10.1517/14728222.12.3.367

M3 - Review article

C2 - 18269345

AN - SCOPUS:41049095471

VL - 12

SP - 367

EP - 376

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 3

ER -